Captopril

Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

ACE InhibitorsCaptopril12.5-50mg PO Q24HAdminister Post HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
21740-502-321-3225-300.7-3N/A40 (high flux)

References:

  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01197
  • Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010; 23(3):290-7.
  • Nonoguchi H, Kiyama S, Kitamura K, et al. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure. Hypertension research : official journal of the Japanese Society of Hypertension. 2008;31(1):29-36. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18360015.
  • Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007;27(5):522-9.